Related Experiment Video
Updated: Jun 19, 2026
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial
Thulo Molefi1,2,3, Lloyd Mabonga2, Rodney Hull2
1Discipline of Obstetrics and Gynaecology, School of Clinical Medicine, University of KwaZulu-Natal, Durban 4002, South Africa.
Abstract:
The peremptory need to circumvent challenges associated with poorly differentiated epithelial endometrial cancers (PDEECs), also known as Type II endometrial cancers (ECs), has prompted therapeutic interrogation of the prototypically intractable and most prevalent gynecological malignancy. PDEECs account for most endometrial cancer-related mortalities due to their aggressive nature, late-stage detection, and poor response to standard therapies. PDEECs are characterized by heterogeneous histopathological features and distinct molecular profiles, and they pose significant clinical challenges due to their propensity for rapid progression. Regardless of the complexities around PDEECs, they are still being administered inefficiently in the same manner as clinically indolent and readily curable type-I ECs. Currently, there are no targeted therapies for the treatment of PDEECs. The realization of the need for new treatment options has transformed our understanding of PDEECs by enabling more precise classification based on genomic profiling. The transition from a histopathological to a molecular classification has provided critical insights into the underlying genetic and epigenetic alterations in these malignancies. This review explores the genomic landscape of PDEECs, with a focus on identifying key molecular subtypes and associated genetic mutations that are prevalent in aggressive variants. Here, we discuss how molecular classification correlates with clinical outcomes and can refine diagnostic accuracy, predict patient prognosis, and inform therapeutic strategies. Deciphering the molecular underpinnings of PDEECs has led to advances in precision oncology and protracted therapeutic remissions for patients with these untamable malignancies.
Insights
Poorly differentiated epithelial endometrial cancers (PDEECs) are aggressive and hard to treat. Genomic profiling offers new ways to classify these cancers, improving diagnosis and guiding targeted therapies for better patient outcomes.
Area of Science:
- Oncology
- Genomics
- Gynecologic Oncology
Background:
- Poorly differentiated epithelial endometrial cancers (PDEECs), or Type II endometrial cancers (ECs), are the most common cause of endometrial cancer mortality.
- These aggressive cancers present significant clinical challenges due to heterogeneous features, late detection, and poor response to conventional treatments.
- Current treatments for PDEECs are often inefficient and lack targeted therapies.
Purpose of the Study:
- To explore the genomic landscape of PDEECs.
- To identify key molecular subtypes and genetic mutations associated with aggressive variants.
- To discuss how molecular classification can refine diagnosis, predict prognosis, and inform therapeutic strategies.
Main Methods:
- Review of the genomic profiling of PDEECs.
- Analysis of molecular classification in relation to clinical outcomes.
- Exploration of genetic and epigenetic alterations in PDEECs.
Main Results:
- Molecular classification provides more precise categorization of PDEECs compared to traditional histopathology.
- Specific molecular subtypes and genetic mutations are linked to aggressive disease variants.
- Genomic insights are transforming the understanding and treatment of PDEECs.
Conclusions:
- Transitioning to molecular classification enhances diagnostic accuracy and prognostic prediction for PDEECs.
- Understanding the molecular underpinnings facilitates precision oncology approaches.
- Deciphering PDEEC genomics paves the way for novel therapeutic strategies and improved patient outcomes.
